Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 14/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL204536 | 0.98 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL536413 | 0.98 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973516 | 0.98 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL2402213 | 0.98 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL2282829 | 0.98 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4421548 | 0.98 | FDPS (0.66) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4279500 | 0.98 | FDPS (0.64) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4424488 | 0.96 | FDPS (0.63) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4284355 | 0.95 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4646149 | 0.95 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7242 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005663-A | Application of aconite in treating kidney-yang deficiency type osteoporosis | 重庆医科大学 | 2026-05-12 | — | — | CN | claimed |
| CN-122005953-A | Drug mineralized gel and preparation method and application thereof | 中国科学院兰州化学物理研究所 | 2026-05-12 | — | — | CN | claimed |
| EP-4324492-B1 | MULTIFUNCTIONAL, HYDROGEL HYBRID MATERIAL, METHOD OF ITS PREPARATION AND USE IN THE TREATMENT OF BONE LOSSES | UNIV JAGIELLONSKI (PL) | 2026-03-04 | — | — | EP | claimed |
| CN-121570641-A | Hydrogel for repairing osteoporosis bone defect and preparation method thereof | 西南交通大学 | 2026-02-27 | — | — | CN | claimed |
| US-20250381141-A1 | Formulation of lecithin-modified calcium phosphate nanoparticles with an enhanced cellar uptake as a carrier for bisphosphonates and a method of preparing thereof | POLITECHNIKA WARSZAWSKA (PL) | 2025-12-18 | — | — | US | claimed |
| US-20250375395-A1 | TRANSDERMAL FORMULATION AND DELIVERY METHOD OF LOW SOLUBILITY OR UNSTABLE UNIONIZED NEUTRAL DRUGS BY IN SITU SALT-TO-NEUTRAL DRUG CONVERSION OF SALT DRUG | CORIUM INTERNATIONAL, INC. | 2025-12-11 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025133965-A2 | RELEASE SYSTEM FOR THE TOPICAL OR INTRA-ARTICULAR ADMINISTRATION OF DRUGS | FIDIA FARMACEUTICI S.P.A. (IT) | 2025-06-26 | — | — | WO | claimed |
| US-12337065-B2 | Compositions for treating viral infections and methods for same | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-06-24 | — | — | US | claimed |
| CN-120154943-A | Hemodialysis adsorbent, preparation method, hemodialysis adsorption column and blood purification device | 上海天佑医院有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-5958908-A | Sodium alendronate preparation for local administration | MERCK & CO., INC. (US) | 1999-09-28 | — | — | US | claimed |
| EP-0939624-A1 | EFFERVESCENT BISPHOSPHONATE FORMULATION | Merck & Co., Inc. (US) | 1999-09-08 | — | — | EP | claimed |
| EP-0938319-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ALENDRONATE AND AN AGENT PROMOTING GASTRIC EMPTYING | Fuisz Technologies Ltd. (US) | 1999-09-01 | — | — | EP | claimed |
| EP-0886521-A1 | TOPICAL BISPHOSPHONATES FOR PREVENTION OF BONE RESORPTION | Binderman, Itzhak (IL) | 1998-12-30 | — | — | EP | claimed |
| US-5773429-A | Drug combination for treating calcium loss | FUISZ TECHNOLOGIES LTD. (US) | 1998-06-30 | — | — | US | claimed |
| WO-1998025628-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ALENDRONATE AND AN AGENT PROMOTING GASTRIC EMPTYING | FUISZ TECHNOLOGIES LTD. (US) | 1998-06-18 | — | — | WO | claimed |
| EP-0831756-A1 | BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES | Merck & Co., Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997044017-A1 | EFFERVESCENT BISPHOSPHONATE FORMULATION | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | claimed |
| WO-1997029754-A1 | TOPICAL BISPHOSPHONATES FOR PREVENTION OF BONE RESORPTION | BINDERMAN ITZHAK (IL) | 1997-08-21 | — | — | WO | claimed |
| WO-1996039107-A1 | BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | claimed |